Skip to main content

Search

Janssen R&D Investment

Janssen reinvests close to one quarter of its sales in R&D

Developing new medicines costs more than ever before. Compared to other industries, pharma is by far the largest investor in R&D both in absolute figures and as a percentage of sales. Almost one-quarter of Janssen’s sales are re-invested in new product research.

 

R&D Investment

Source: EU Industrial R&D Scoreboard, 2010